Renaissancere Holdings Ltd (RNR) Stock “Hold” Rating Reiterated at KBW; The Price Target is Set to $143.0; Ohr Pharmaceutical (OHRP)’s Sentiment Is 1.44

February 2, 2018 - By Darrin Black

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The company has market cap of $17.70 million. The Company’s lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. It currently has negative earnings. The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion.

Among 15 analysts covering RenaissanceRe (NYSE:RNR), 2 have Buy rating, 0 Sell and 13 Hold. Therefore 13% are positive. RenaissanceRe has $165.0 highest and $115 lowest target. $137.90’s average target is 5.51% above currents $130.7 stock price. RenaissanceRe had 28 analyst reports since October 14, 2015 according to SRatingsIntel. The stock of RenaissanceRe Holdings Ltd. (NYSE:RNR) earned “Hold” rating by J.P. Morgan on Friday, July 28. Nomura upgraded the stock to “Neutral” rating in Monday, December 7 report. Wells Fargo maintained the stock with “Hold” rating in Tuesday, January 9 report. The stock of RenaissanceRe Holdings Ltd. (NYSE:RNR) earned “Hold” rating by Keefe Bruyette & Woods on Wednesday, September 20. RBC Capital Markets maintained RenaissanceRe Holdings Ltd. (NYSE:RNR) rating on Thursday, February 4. RBC Capital Markets has “Sector Perform” rating and $117 target. The firm has “Buy” rating given on Monday, September 11 by Buckingham Research. UBS maintained it with “Neutral” rating and $136 target in Tuesday, September 19 report. The firm has “Market Perform” rating given on Monday, July 11 by Wood. On Thursday, August 17 the stock rating was maintained by Keefe Bruyette & Woods with “Hold”. The firm has “Neutral” rating given on Monday, October 2 by Citigroup.




Analysts await OHR Pharmaceutical, Inc. (NASDAQ:OHRP) to report earnings on February, 13. They expect $-0.07 earnings per share, up 66.67% or $0.14 from last year’s $-0.21 per share. After $-0.08 actual earnings per share reported by OHR Pharmaceutical, Inc. for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

The stock decreased 1.01% or $0.0032 during the last trading session, reaching $0.3149. About 1.27 million shares traded. OHR Pharmaceutical, Inc. (OHRP) has declined 77.87% since February 2, 2017 and is downtrending. It has underperformed by 94.57% the S&P500.

Garrison Bradford & Associates Inc holds 0.3% of its portfolio in OHR Pharmaceutical, Inc. for 497,415 shares. Leisure Capital Management owns 64,067 shares or 0.04% of their US portfolio. Moreover, Cannell Peter B & Co Inc has 0.01% invested in the company for 292,858 shares. The Missouri-based Cutter & Co Brokerage Inc. has invested 0.01% in the stock. Sabby Management Llc, a New Jersey-based fund reported 152,127 shares.

The stock increased 2.80% or $3.56 during the last trading session, reaching $130.7. About 540,727 shares traded or 25.20% up from the average. RenaissanceRe Holdings Ltd. (NYSE:RNR) has risen 20.88% since February 2, 2017 and is uptrending. It has outperformed by 4.18% the S&P500.

RenaissanceRe Holdings Ltd. together with its subsidiaries, provides reinsurance and insurance coverages and related services in the United States and internationally. The company has market cap of $5.23 billion. The firm operates through Property, and Casualty and Specialty divisions. It currently has negative earnings. The Property segment writes property catastrophe excess of loss reinsurance contracts to insure insurance and reinsurance companies against natural and man-made catastrophes, such as earthquakes, hurricanes, and tsunamis, as well as claims arising from other natural and man-made catastrophes comprising winter storms, freezes, floods, fires, windstorms, tornadoes, explosions, and acts of terrorism; and other property class of products, including proportional reinsurance, property per risk, property reinsurance, and binding facilities and regional U.S. multi-line reinsurance.

Investors sentiment decreased to 0.9 in 2017 Q3. Its down 0.27, from 1.17 in 2017Q2. It worsened, as 31 investors sold RenaissanceRe Holdings Ltd. shares while 105 reduced holdings. 42 funds opened positions while 80 raised stakes. 36.70 million shares or 1.16% more from 36.28 million shares in 2017Q2 were reported. Schwab Charles Invest Mgmt holds 0.02% or 148,981 shares. West Oak Cap Ltd Limited Liability Company stated it has 0% of its portfolio in RenaissanceRe Holdings Ltd. (NYSE:RNR). Moreover, Credit Suisse Ag has 0.02% invested in RenaissanceRe Holdings Ltd. (NYSE:RNR). Geode Mngmt Ltd holds 0.02% or 371,533 shares. Teacher Retirement Sys Of Texas owns 0.03% invested in RenaissanceRe Holdings Ltd. (NYSE:RNR) for 35,562 shares. Louisiana State Employees Retirement Sys owns 10,800 shares. Old Mutual Customised Solutions (Proprietary) has invested 0.02% in RenaissanceRe Holdings Ltd. (NYSE:RNR). Pnc Fincl Svcs Group Inc holds 0% of its portfolio in RenaissanceRe Holdings Ltd. (NYSE:RNR) for 1,987 shares. Johnson Investment Counsel has 0.2% invested in RenaissanceRe Holdings Ltd. (NYSE:RNR). Jacobs Levy Equity Mgmt accumulated 5,450 shares. Peak6 Ltd Partnership owns 8,854 shares for 0.01% of their portfolio. Proshare Advsr Limited Liability Company holds 0.09% of its portfolio in RenaissanceRe Holdings Ltd. (NYSE:RNR) for 72,498 shares. Panagora Asset reported 4,343 shares. Deutsche Financial Bank Ag owns 70,455 shares. Hrt Fincl Lc reported 4,048 shares.

Since October 2, 2017, it had 0 insider purchases, and 1 insider sale for $674,444 activity. $674,444 worth of RenaissanceRe Holdings Ltd. (NYSE:RNR) was sold by ODonnell Kevin.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: